Skip to main content
SpringerLink
Log in

The Phase I Study: General Objectives, Methods, and Evaluation

  • Chapter
Clinical Evaluation of Antitumor Therapy

Part of the book series: Developments in Oncology ((DION,volume 46))

Abstract

No curative therapy exists for most patients with metastatic cancer. However, the fact that a few types of metastatic cancer can be cured with chemotherapy lends encouragement to the search for new effective agents. Since it is possible to cure childhood leukemia and testicular carcinoma with currently available drug regimens, it is not implausible to assume that drugs may become available that will cure bronchogenic or colorectal carcinoma. Certainly, drug therapy remains the most promising avenue of research for the cure of metastatic cancer at the present time. Consequently, the evaluation of new antitumor agents is an endeavor with the highest priority.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Similar content being viewed by others

References

  1. VonHoff DD, Rozencweig M, Soper WT, Helman LJ, Penta JS, Davis HL, Muggia FM. Whatever happened to NSC? Cancer Treat Rep 61: 759–768, 1977.

    Google Scholar 

  2. Smythe JF, Paine RM, Jackman AL, Harrap KR, Chassin MM, Adamson RH, Johns DG. The clinical pharmacology of the adenosine deaminase inhibitor 2′-deoxycoformycin. Cancer Chemother Pharmacol 5: 93–101, 1980.

    Article  Google Scholar 

  3. Tobias JS, Tattersall MHN. Doing the best for the cancer patient. Lancet 1: 35–38, 1985.

    Article  PubMed  CAS  Google Scholar 

  4. Muggia FM, DeVita VT Jr. Comments on moral dilemmas in clinical cancer experimentation. Med Ped Oncol 4: 181, 1978.

    Article  CAS  Google Scholar 

  5. Prieur DJ, Young DM, Davis RD, Cooney DA, Homan ER, Dixon RL, Guarino AM. Procedures for preclinical toxicologic evaluation of cancer chemotherapeutic agents: Protocols of the laboratory of toxicology. Cancer Chemother Rep 4: 1–30, 1973.

    CAS  Google Scholar 

  6. DeVita VT, Oliverio VT, Muggia FM, Wiernik PW, Ziegler J, Goldin A, Rubin D, Henney J, Schepartz S. The drug development and clinical trials programs of the Division of Cancer Treatment, National Cancer Institute. Cancer Clin Trials 2: 195–216, 1979.

    Google Scholar 

  7. Collins JM. Pharmacology in drug development. Cancer Treat Rep. (To be published.)

    Google Scholar 

  8. Powis G. Pharmacology and pharmacology reviews. Cancer Chemother & Pharm.

    Google Scholar 

  9. Yesair DW. Lipid macromolecules as chemotherapeutic target. In Experimental & Clinical Progress in Cancer Chemotherapy, Muggia FM (ed). Boston: Martinus Nijhoff, 1985, pp. 13–60.

    Chapter  Google Scholar 

  10. Bodey GP, Gottlieb J, McCredie KB, Freireich EJ. Adenine arabinoside in cancer chemotherapy. In Adenine Arabinoside: An Antiviral Agent. New York: Raven Press, 1975, pp. 281–285.

    Google Scholar 

  11. Aoshima M, Tsukagoshi S, Sakurai Y, Oh-ishi J-I, Ishida J, Kobayashi H. N4-behenoyl-1-B-D-arabinofuranosylcytosine as a potential new antitumor agent. Cancer Res 37: 2481–2486, 1977.

    PubMed  CAS  Google Scholar 

  12. Freireich EJ, Gehan EA, Rail DP, Schmidt LH, Skipper HE. Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man. Cancer Chemother Rep 50: 219–244, 1966.

    PubMed  CAS  Google Scholar 

  13. Homan ER. Quantitative relationships between toxic doses of antitumor chemotherapeutic agents in animals and man. Cancer Chemother Rep 3: 13–19, 1972.

    CAS  Google Scholar 

  14. Goldsmith MA, Slavik M, Carter SK. Quantitative prediction of drug toxicity in humans from toxicology in small and large animals. Cancer Res 35: 1354–1364, 1975.

    PubMed  CAS  Google Scholar 

  15. Penta JS, Rozencweig M, Guarino AM, Muggia FM. Mouse and large-animal toxicology studies of twelve anticancer agents: Relevance to starting dose for phase I clinical trials. Cancer Chemother Pharmacol 3: 97–101, 1979.

    Article  PubMed  CAS  Google Scholar 

  16. Guarino AM, Rozencweig M, Kline I, Penta JS, Venditti JM, Lloyd HH, Holzworth DA, Muggia FM. Adequacies and inadequacies in assessing murine toxicity data with antineoplastic agents. Cancer Res 39: 2204–2210, 1979.

    PubMed  CAS  Google Scholar 

  17. Rozencweig M, Van Hoff DD, Staquet MJ, Schein PS, Penta JS, Goldin A, Muggia FM, Freireich EJ, De Vita VT. Animal toxicology for early clinical trials with anticancer agents. Cancer Clin Trials 4: 21–28, 1981.

    PubMed  CAS  Google Scholar 

  18. Schein PS, Davis RD, Carter S, Newman J, Schein DR, Rall DP. The evaluation of anticancer drugs in dogs and monkeys for the prediction of qualitative toxicities in man. Clin Pharmacol Therap 11: 3–40, 1970.

    CAS  Google Scholar 

  19. Bodey GP, Freireich EJ, Monto RW, Hewlett JS. Cytosine arabinoside chemotherapy for acute leukemia in adults. Cancer Chemother Rep 53: 59–66, 1969.

    PubMed  CAS  Google Scholar 

  20. Yap HY, Blumenschein GR, Keating MJ, Hortobagyi GN, Tashima CK, Loo TL. Continuous 5-day infusion vinblastine in the treatment of refractory advanced breast cancer. Cancer Treat Rep 64: 279–283, 1980.

    PubMed  CAS  Google Scholar 

  21. Legha SS, Benjamin RS, Mackay B, Yap HY, Wallace S, Ewer M, Blumenschein GR, Bodey, GP. Adriamycin therapy by continuous intravenous infusion in patients with metastatic breast cancer. Cancer 49: 1762–1766, 1982.

    Article  PubMed  CAS  Google Scholar 

  22. DeVita VT, Gold GL, Owens AH, Miller JM. Preliminary studies with 1,3-bis-(2-chloroethyl)-1 nitrosourea (BCNU). (Abstract). Proc Am Assoc Cancer Res 5: 15, 1965.

    Google Scholar 

  23. Hansen HH, Selawry OS, Muggia FM, Walker MD. Clinical studies with 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (NSC 79037). Cancer Res 31: 223–227, 1971.

    PubMed  CAS  Google Scholar 

  24. Schneiderman MA. Mouse to man: Statistical problems in bringing a drug to clinical trial. Proceedings of the Fifth Berkeley Symposium on Mathematical Statistics and Probability. University of California Press, 1967.

    Google Scholar 

  25. Carter SK, Goldin A. Experimental models and their clinical correlations. National Cancer Institute Monograph 45: Development of New Anticancer Drugs. 1977, pp. 63–74.

    Google Scholar 

  26. Kutcher J, Gailani S. Phase I study of 1-(2-chloroethyl)-3-(4-methylcyclohexyl)-1-nitrosourea (Me-CCNU) in cancer patients. Clin Res 20: 568, 1972.

    Google Scholar 

  27. Gottlieb JA, McCredie KB, Hersh EM, Frei E HI. Initial clinical studies with 1-2-(chloroethyl)-3-(4-methylcyclohexyl)-1-nitrosourea (methyl CCNU). (Abstract). Proc Am Assoc Cancer Res 13: 79, 1972.

    Google Scholar 

  28. Young RC, Walker MD, Canellos GP, Schein PS, Chabner BA, DeVita VT. Initial clinical trials with methyl-CCNU 1-(2-chloroethyl)-3-(4-methylcyclohexyl)-1-nitrosourea (Me CCNU). Cancer 31: 1164–1169, 1973.

    Article  PubMed  CAS  Google Scholar 

  29. Ho DHW. Clinial pharmacology of 1-β-D-arabinofuranosyl cytosine. Clin Pharmacol Therap 12: 944–954, 1971.

    CAS  Google Scholar 

  30. Bleyer AW. The clinical pharmacology of methotrexate. New applications of an old drug. Cancer 41: 36–51, 1978.

    Article  PubMed  CAS  Google Scholar 

  31. Benjamin RS, Wiernik PH, Bachur NR. Adriamycin chemotherapy-efficacy, safety and pharmacologic basis of an intermittent schedule. Cancer 33: 19–27, 1974.

    Article  PubMed  CAS  Google Scholar 

  32. Vietti TJ. Evaluation of toxicity: Clinical issues. Cancer Treat Rep 64: 457–461, 1980.

    PubMed  CAS  Google Scholar 

  33. Bodey GP, Gottlieb JA, Burgess MA, Alexanian R. Clinical evaluation of asaley. Med Pediat Oncol 3: 365–371, 1977.

    Article  CAS  Google Scholar 

  34. Valdivieso M, Bodey GP, Gottlieb JA, Freireich EJ. Clinical evaluation of ftorafur (pyrimi-dine-deoxyribose N1′-furanidyl-5-fluorouracil). Cancer Res 36: 1821–1824, 1976.

    PubMed  CAS  Google Scholar 

  35. McKelvey EM, Burgess MA, McCredie KB, Murphy WK, Bodey GP. Neocarzinostatin: A phase I clinical trial with five-day intermittent and continuous infusion. Cancer 44: 1182–1188, 1979.

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. Gerald P. Bodey
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sewa S. Legha
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Norris Cancer Hospital, USC School of Medicine, USC Comprehensive Cancer Center, 1441 Eastlake Avenue, Room 162, Los Angeles, CA, 90033, USA

    Franco M. Muggia M.D.

  2. Pharmaceutical Research and Development Division, Bristol-Myers Company and New York University Medical Center, P.O. Box 4755, Syracuse, NY, 13221-4755, USA

    Marcel Rozencweig M.D.

Rights and permissions

Reprints and permissions

Copyright information

© 1987 Martinus Nijhoff Publishing, Boston

About this chapter

Cite this chapter

Bodey, G.P., Legha, S.S. (1987). The Phase I Study: General Objectives, Methods, and Evaluation. In: Muggia, F.M., Rozencweig, M. (eds) Clinical Evaluation of Antitumor Therapy. Developments in Oncology, vol 46. Springer, Boston, MA. https://doi.org/10.1007/978-1-4613-2317-4_8

Download citation

  • DOI: https://doi.org/10.1007/978-1-4613-2317-4_8

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4612-9425-2

  • Online ISBN: 978-1-4613-2317-4

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation